President Trump recently criticized the FDA approval process as "slow and burdensome" but failed to offer up specific plans for reform. If FDA standards were to be altered, the market could see an avalanche of new drugs and treatments. TheStreet's Adam Feuerstein compiled the "Gnarly Nine" companies that could be interesting to watch as the FDA enters the Trump era. 

  1. Alkermes (ALKS - Get Report)
  2. CytRX (CYTR - Get Report)

  3. Dynavax Technologies (DVAX - Get Report)

  4. Intra-Cellular Therapies (ITCI)

  5. Novan (NOVN - Get Report)

  6. Portola Pharmaceuticals (PTLA - Get Report)

  7. PTC Therapeutics (PTCT - Get Report)

  8. Rigel Pharmaceuticals (RIGL - Get Report)

  9. TG Therapeutics (TGTX - Get Report)

READ THE FULL STORY HERE: These 'Gnarly 9' Biotechs Will Test the FDA's Mettle

This article was written by a staff member of TheStreet.